Materias dentro de su búsqueda.
Mostrando 241 - 260 Resultados de 4,168 Para Buscar '"IDH"', tiempo de consulta: 0.15s Limitar resultados
  1. 241
    “…Recent studies suggest that glioblastomas (GBMs) contacting the subventricular zone (SVZ) as the main adult neurogenic niche confer a dismal prognosis but disregard the unique molecular and prognostic phenotype associated with isocitrate dehydrogenase 1 (IDH1) mutations. We therefore examined location-dependent prognostic factors, growth, and recurrence patterns in a consecutive cohort of 285 IDH1-wildtype GBMs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
  2. 242
    “…However, whether there are differences in their representation and activity in the prognostically-favorable isocitrate dehydrogenase (IDH)-mutated compared to -wild type GBMs is unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
  3. 243
    “…We retrospectively analyzed a clinically and molecularly very well-characterized cohort of 111 IDH wildtype glioblastoma patients, who underwent gross total tumor resection and received standard Stupp treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
  4. 244
    “…Also, venetoclax, CB-839, PARP inhibitors, and IDH1 peptide vaccine are being studied in IDH1(mut) AML. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IDH1-mutated relapsed or refractory AML: current challenges and future prospects
  5. 245
    “…Here, we report that tumor-derived IDH1 mutation sensitizes cells to ferroptosis. Deletion of the mutant IDH1 allele in IDH1 heterozygous tumor cells or pharmacological inhibition of mutant IDH1 to produce the oncometabolite D-2-hydroxyglutarate (D-2-HG) confers resistance to erastin-induced ferroptosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
  6. 246
    “…The detection of IDH mutations in patients with diffusely infiltrating malignant astrocytomas resulted in substantial modifications in the concept of WHO classification of these tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
  7. 247
    “…IDH1/2 mutations are early drivers present in diverse human cancer types arising in various tissue sites. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
  8. 248
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses
  9. 249
    “…Materials and methods: We analyzed a series of 116 patients with IDH-1 wild type GBM and different EOR (Gross Total Resection—GTR-, Partial Resection—PR- and Biopsy), treated with adjuvant chemo-radiotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
  10. 250
    “…Mutations in isocitrate dehydrogenase (IDH) genes occur in multiple cancer types, lead to global changes in the epigenome, and drive tumorigenesis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
  11. 251
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
  12. 252
    “…OBJECTIVE: IDH mutations diversely affect the prognosis of cyogenetically normal acute myeloid leukemia (CN-AML) adult patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
  13. 253
    “…IDH-mutant astrocytomas are well-recognized in the adult population and while increasingly identified, are rare in children and young adults. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
  14. 254
    “…BACKGROUND: Driver genes of GBM may be crucial for the onset of isocitrate dehydrogenase (IDH)-wildtype (WT) glioblastoma (GBM). However, it is still unknown whether the genes are expressed in the identical cluster of cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
  15. 255
    “…Inclusion criteria were defined as follows: patients older than 18 years, histopathological, and molecularly defined IDH wild-type glioma, major tumor mass (at least 2/3) invading the corpus callosum in the sagittal plane with a uni- or bilateral infiltration of the adjacent lobules. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Surgery for IDH1/2 wild-type glioma invading the corpus callosum
  16. 256
    por Stuani, Lucille, Sabatier, Marie, Saland, Estelle, Cognet, Guillaume, Poupin, Nathalie, Bosc, Claudie, Castelli, Florence A., Gales, Lara, Turtoi, Evgenia, Montersino, Camille, Farge, Thomas, Boet, Emeline, Broin, Nicolas, Larrue, Clément, Baran, Natalia, Cissé, Madi Y., Conti, Marc, Loric, Sylvain, Kaoma, Tony, Hucteau, Alexis, Zavoriti, Aliki, Sahal, Ambrine, Mouchel, Pierre-Luc, Gotanègre, Mathilde, Cassan, Cédric, Fernando, Laurent, Wang, Feng, Hosseini, Mohsen, Chu-Van, Emeline, Le Cam, Laurent, Carroll, Martin, Selak, Mary A., Vey, Norbert, Castellano, Rémy, Fenaille, François, Turtoi, Andrei, Cazals, Guillaume, Bories, Pierre, Gibon, Yves, Nicolay, Brandon, Ronseaux, Sébastien, Marszalek, Joseph R., Takahashi, Koichi, DiNardo, Courtney D., Konopleva, Marina, Pancaldi, Véra, Collette, Yves, Bellvert, Floriant, Jourdan, Fabien, Linares, Laetitia K., Récher, Christian, Portais, Jean-Charles, Sarry, Jean-Emmanuel
    Publicado 2021
    “…Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias, and susceptibility to mitochondrial inhibitors in cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
  17. 257
    “…The values of CBF1, CBF3, rCBF1-2, rCBF3-2, D*1, and age in group IDH1(mut) were significantly lower than that of in group IDH1(wt). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI
  18. 258
    “…Although isocitrate-dehydrogenase (IDH) gene mutation has been identified as a more favorable prognostic factor, most IDH-mutated AG patients are confronted with tumor recurrence. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence
  19. 259
    “…Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
  20. 260
    por Sun, Xueyuan, Turcan, Sevin
    Publicado 2021
    “…In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Herramientas de búsqueda: RSS